Amerise Biosciences files SEBI disclosure on share acquisition by Snehjeev Ventures and PACs

What Amerise Biosciences announced

On 17 July 2026, Amerise Biosciences Ltd submitted a disclosure to the Bombay Stock Exchange under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing states that Snehjeev Ventures Pvt Ltd and persons acting in concert (PACs) have acquired shares in Amerise Biosciences, thereby triggering the mandatory reporting requirement.

"The Exchange has received the disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 for Snehjeev Ventures Pvt Ltd & PACs."

The company did not provide further quantitative details—such as the number of shares purchased or the percentage of total equity—within the filing.

Parties involved and regulatory context

• Snehjeev Ventures Pvt Ltd – identified as the acquirer. The filing does not elaborate on the entity’s background or its strategic intent.
• Persons Acting in Concert (PACs) – refers to individuals or entities that have agreed to act together in exercising voting rights or influencing the company’s management. Under SEBI rules, the holdings of PACs are aggregated with that of the principal acquirer.
• Regulation 29(2) of SEBI SAST Regulations, 2011 – mandates that any person or group acquiring shares that cross the 1 % threshold (or any subsequent thresholds of 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 50 % and 75 %) must disclose the acquisition to the stock exchange within two trading days of the transaction.

The filing therefore serves as a compliance instrument, ensuring transparency for existing shareholders and the market.

Key facts at a glance

Why this matters for investors

The disclosure signals that a new shareholder—or a group of coordinated shareholders—has taken a material position in Amerise Biosciences. While the exact size of the stake is unknown, the requirement to file under Reg 29(2) indicates that the acquisition has crossed at least the 1 % threshold. Investors should monitor subsequent filings for:

• Updated shareholding percentages once the acquirer’s exact stake is quantified.
• Any statements from Snehjeev Ventures regarding its strategic intent (e.g., board representation, capital infusion, or potential restructuring).
• Potential regulatory approvals if the stake approaches higher thresholds that may trigger mandatory open‑offer obligations under the SAST framework.

Conclusion

Amerise Biosciences has complied with SEBI’s disclosure norms by reporting that Snehjeev Ventures Pvt Ltd and its PACs have acquired shares in the company. The filing does not reveal the magnitude of the holding, leaving investors to await further disclosures that will clarify the extent of the acquisition and any consequent corporate actions.